Delving into the Latest Updates on Tobramycin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Concentrated Divitamins and Sodium, Concentrated Divitamins and Sodium Phoshate Syrup, Concentrated Divitamins and Sodium Phosp

+ [25]

Target

30S subunit

Action

inhibitors

Mechanism

30S subunit inhibitors(30S ribosomal subunit inhibitors)

Therapeutic Areas

Infectious DiseasesCongenital DisordersDigestive System Disorders+ [5]

Active Indication

BronchiectasisCystic FibrosisInfectious Lung Disorder+ [17]

Inactive Indication

CataractChronic sinusitisNon-cystic fibrosis bronchiectasis+ [1]

Originator Organization

Eli Lilly & Co.

Active Organization

Viatris Healthcare (Pty) Ltd.Pulmoflow, Inc.PARI Pharma GmbH

+ [12]

Inactive Organization

Shenzhen Taitai Pharmaceutical Co., Ltd.

Novartis Pharmaceuticals Canada, Inc.

Shanghai Fangyu Health Pharmaceutical Technology Co., Ltd.

+ [5]

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (12 Dec 1980),

Bacterial Infections

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC18H37N5O9

InChIKeyNLVFBUXFDBBNBW-PBSUHMDJSA-N

CAS Registry32986-56-4

HCO₃^- is involved in pH homoeostasis and plays a multifaceted role in human health. HCO₃^- has been recognized for its antimicrobial properties and is pivotal in bacterial antibiotic susceptibility. Notably, the interconversion between CO₂ and HCO₃^-, facilitated by the enzyme carbonic anhydrase (CA), is crucial in tissues infected by pathogens. Studies have highlighted the antimicrobial potency of CA inhibitors, emphasizing the importance of this enzyme in this area. The potential of HCO₃^- as an antibiotic adjuvant is evident; its ability to increase virulence in pathogens such as Enterococcus faecalis and Mycobacterium tuberculosis requires meticulous scrutiny. HCO₃^- modulates bacterial behaviours in diverse manners: it promotes Escherichia coli O157:H7 colonization in the human gut by altering specific gene expression and, with Pseudomonas aeruginosa, amplifies the effect of tobramycin on planktonic cells while promoting biofilm formation. These multifaceted effects necessitate profound mechanistic exploration before HCO₃^- can be considered a promising clinical adjuvant.

31 Dec 2025·Virulence

Article

Author: Alcàcer-Almansa, Júlia ; Torrents, Eduard ; Blanco-Cabra, Núria

Multispecies biofilms are communities composed of different microorganisms embedded in an auto-synthesized polymeric matrix. Pseudomonas aeruginosa and Burkholderia cenocepacia are two multidrug-resistant and biofilm-forming opportunistic pathogens often found in the lungs of people living with cystic fibrosis. In this context, planktonic, static, and dynamic biofilms and in vivo models of both species were optimized in this work to understand their population dynamics, disposition, virulence, and antibiotic susceptibility. From the coculture models optimized in this work, we determined that B. cenocepacia grows in a clustered, aggregative manner at the bottom layers of biofilms, in close contact with P. aeruginosa, that tends to occupy the top layers. Their coexistence increases virulence-related gene expression in both species at early stages of coinfection and in in vivo models, while there was a general downregulation of virulence-related genes after longer coexistence periods as they eventually reach a non-competitive stage during chronic infections. When evaluating antimicrobial susceptibility, a decrease of antimicrobial tolerance was observed in both species when co-cultured. These findings shed light on the differential behavior of P. aeruginosa and B. cenocepacia in dual-species systems, stressing the relevance of multispecies studies in the clinical context.

01 Dec 2025·MOLECULAR BIOLOGY REPORTS

Targeted inhibition of PqsR in Pseudomonas aeruginosa PAO1 quorum-sensing network by chalcones as promising antibacterial compounds

Article

Author: Soheili, Vahid ; Tajani, Amineh Sadat ; Bazzaz, Bibi Sedigheh Fazly ; Rezaei, Tahoura ; Hashemi, Maryam ; Ghodsi, Razieh ; Arami, Negin

BACKGROUND:

Pseudomonas aeruginosa's inherent and adapted resistance makes this pathogen a serious problem for antimicrobial treatments. Furthermore, its biofilm formation ability is the most critical armor against antimicrobial therapy, and the virulence factors, on the other hand, contribute to fatal infection and other recalcitrant phenotypic characteristics. These capabilities are harmonized through cell-cell communication called Quorum Sensing (QS), which results in gene expression regulation via three major interconnected circuits: las, rhl, and pqs system. Pqs circuit specificity in P. aeruginosa made this system an attractive target for antipseudomonal therapy. The current study focuses on novel chalcone derivatives that attenuate P. aeruginosa's pathogenicity by inhibiting the QS system. Chalcones are included in the flavonoid class of phenolic compounds. This family forms one of the greatest groups of bioactive natural products.

METHOD:

The chalcone derivatives's potential activity against the QS system was evaluated through biofilm inhibition, decreased virulence factors production, and gene expression.

RESULTS:

Among all the tested compounds, 5H and NMe₂ chalcone derivatives reduced biofilm formation by 60.9% and 78.9%, respectively, and virulence factors production, including pyocyanin (decreased by 5H 30.9% and NMe2 30.7%) and pyoverdine (decreased by 5H 47.1% and NMe2 56.9%) and the QS gene expression (LasR, RhlR, and PqsR) more effectively than other derivatives.

CONCLUSION:

These chalcone compounds can be used as a supplement besides antimicrobial chemotherapy to attenuate pseudomonas pathogenicity.

75

News (Medical) associated with Tobramycin

08 Jul 2025

·www.businesswire.com

Sound Pharma to Present at Upcoming Life Sciences Industry Conferences

SEATTLE--(BUSINESS WIRE)--Sound Pharmaceuticals is pleased to announce that it has been invited to present its R&D and financing goals at two upcoming industry conferences this month. 5 th Inner Ear Disorders Therapeutics Summit on July 15-17 BTIG Virtual Biotechnology Conference July 29-30 Dr. Jonathan Kil, Co-Founder and CEO, will provide an update on SPI-1005, a novel oral anti-inflammatory drug. SPI-1005 is the first investigational drug to achieve its co-primary endpoints, involving pure-tone audiometry and words-in-noise test, in a pivotal Phase 3 randomized, double blinded, placebo-controlled trial (RCT) to treat Meniere’s Disease (STOPMD-3). There are no FDA approved drugs for the treatment of hearing loss, tinnitus, dizziness or vertigo, the primary or core symptoms of Meniere’s Disease (MD). SPI-1005 has also achieved favorable safety and efficacy results in five different RCTs involving MD, acute noise-induced hearing loss, and aminoglycoside-induced ototoxicity. An open-label Phase 3 is starting now that will enroll MD participants to accrue additional safety data to allow for the chronic dosing of SPI-1005 in MD. About SPI-1005 SPI-1005 is an investigational new drug that contains ebselen, a new chemical entity that mimics and induces glutathione peroxidase (GPx) activity. GPx1 is a critical enzyme that repairs injured and aging cells in the inner ear, retina, prefrontal cortex, lung, and kidney, and is reduced during and after exposure to environmental insults such as noise, ototoxic drugs, or aging. Consequently, neuroinflammation can progress throughout the peripheral and central nervous system leading to neurodegeneration and/or maladaptive plasticity. SPI-1005 is being developed for several neurotologic indications including Meniere’s disease (hearing loss, tinnitus, intermittent dizziness, and episodic vertigo), noise-induced hearing loss (including tinnitus) and two types of ototoxicity (hearing loss, tinnitus, dizziness, or vertigo) caused by aminoglycoside antibiotics (such as tobramycin or amikacin) or platinum-based chemotherapy (such as cisplatin or carboplatin). To date, no significant drug-drug interactions have been observed across multiple study populations including Meniere’s disease, patients with cystic fibrosis, bipolar mania, and treatment-resistant depression. Thirteen completed SPI-1005 trials have treated 790 patients with 400+ more enrolled patients anticipated over the next year. About Sound Pharmaceuticals Sound Pharma is a private biotechnology company studying SPI-1005 under five active INDs involving several neurotologic indications. Details of the SPI-1005 clinical trials can be viewed online at www.clinicaltrials.gov or www.soundpharma.com.

Phase 3Clinical Result

27 Jun 2025

·investors.hcwbiologics.com

HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

Tetra-functional T-cell engagers activate T cells and simultaneously reduce immunosuppression, with potent and antigen-specific anti-pancreatic cancer activities at dose levels that are well tolerated Presentation at the Phoenix Best Science Series by HonorHealth Research Institute on June 27, 2025 in Scottsdale, Arizona MIRAMAR, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, announced today that its scientists have successfully developed second-generation, multi-specific T-cell engagers against solid tumors, particularly for pancreatic cancer, using its novel proprietary TRBC product discovery and development platform technology. The TRBC technology enabled the Company to construct T-cell engagers that not only target cancer antigens and CD3 activation of effector T cells, but also simultaneously reduce the immunosuppression in tumor microenvironment. Such immunosuppression plays a pivotal role in reducing effector T-cell infiltration and anti-tumor efficacy in solid tumors. The Company’s two lead T-cell engagers target tissue factor and mesothelin, which are proven solid tumor antigens. These product candidates exhibit potent and antigen-specific anti-pancreatic cancer activities both in vitro and in humanized mouse models at dose levels that are well tolerated. Dr. Hing C. Wong, Founder and CEO of the Company, will present the details of these IND-enabling studies as an invited speaker for the Phoenix Best Science Series, hosted by HonorHealth Research Institute, located at HonorHealth Scottsdale Shea Medical Center in Scottsdale, Arizona, on June 27, 2025. Dr. Wong stated, “T-cell engagers revolutionized the immunotherapeutic approach against cancer. Currently, T-cell engagers have approval from the U.S. Food and Drug Administration to be used in the treatment of a small number of indications, including various hematological and solid tumors. Now, we are very excited to report that our proprietary TRBC product discovery platform can be used to create potentially highly effective T-cell engagers against difficult-to-treat solid tumors by using exceptional targets while managing immunosuppression. In our preclinical studies, after treatment with our TRBC-based T-cell engagers, there was 100% survival among tumor-bearing mice in the test group, whereas none of the untreated mice survived. We believe our approach could expand the number of indications that can be treated with T-cell engagers, including enhancing health span for patients suffering with solid tumors, especially diseases such as pancreatic cancer and glioblastoma.” Dr. Wong continued, “I am very honored to be invited to present at the Phoenix Best Science Series, organized by HonorHealth Research Institute, and join a renowned group of medical and research experts who are at the forefront of the treatment of pancreatic cancer. I look forward to sharing, with this esteemed group, our findings and the basis for our confidence in the potential of our innovative TRBC technology and its derived T-cell engagers against pancreatic cancer and other solid tumors. We believe we are at the cutting edge for expanding the indications that may be treated with T-cell engagers.” About HCW Biologics: HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The Company’s immunotherapeutics represent a new class of drug that it believes have the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation — and in doing so, improve patients’ quality of life and potentially extend longevity. Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to senescence-associated diseases and conditions that diminish healthspan, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as many indications that impact quality-of-life that are not life-threatening. The Company’s lead product candidate, HCW9302, was developed using the Company’s legacy TOBI™ (Tissue factOr-Based fusIon) platform. The Company has created another drug discovery technology, the TRBC platform, which is not based on Tissue Factor. The TRBC platform has the capability to construct immunotherapeutics that not only activate and target immune responses but are also equipped with receptors that specifically target cancerous or infected cells. This platform is a versatile scaffold that enables the creation of multiple classes of immunotherapeutic compounds: Class I: Multi-Functional Immune Cell Stimulators; Class II: Second-Generation Immune Checkpoint Inhibitors; Class III: Multi-Specific Targeting Fusions and Enhanced Immune Cell Engagers. These novel immunotherapeutics can be used to treat a wide range of disease indications, including oncology, autoimmune diseases, and improving quality of life conditions. The Company has constructed over 50 molecules using the TRBC platform, including HCW11-002, HCW11-006, HCW11-018 and HCW11-027. Further preclinical evaluation studies are currently being conducted for these three molecules the Company has selected based on promising early data. The Company has two licensing programs in which it has licensed exclusive rights for some of its proprietary molecules. See the Company Pipeline at https://hcwbiologics.com/pipeline/ Forward Looking Statements: Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words and include, the potential for a future transaction and sharing proceeds therefrom; the actual success and potency of T-cell engagers; whether T-cell engagers have antigen-specific anti-pancreatic cancer activities both in vitro and in humanized mouse models at dose levels that are well tolerated; whether T-cell engagers are effective in treatment of solid tumors and pancreatic cancers. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled “Risk Factors” in the annual report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 28, 2025, the latest Form 10-Q filed with the SEC on May 15, 2025 and in other filings filed from time to time with the SEC. Company Contact: Dr. Peter Rhode Chief Scientific Officer and Vice President of Clinical Operations HCW Biologics Inc. PeterRhode@HCWBiologics.com

ImmunotherapyClinical Study

26 Jun 2025

·investors.hcwbiologics.com

HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

Company in full compliance for continued listing MIRAMAR, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, announced today that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement as required by Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”). On June 24, 2025, HCWB received formal notice from Nasdaq confirming that the Company has satisfied the requirements of the Equity Rule. On May 13, 2025, the Company received formal notice from Nasdaq that it regained compliance with the bid price requirement in Listing Rule 5550(a)(2), the public float requirement in Listing Rule 5550(a)(4), and the market value of publicly held shares requirement in Listing Rule 5550(a)(5). Therefore, the Company now meets all Nasdaq Capital Market listing requirements for continued listing, and these matters are closed. About HCW Biologics: HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The Company’s immunotherapeutics represent a new class of drug that it believes have the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation — and in doing so, improve patients’ quality of life and potentially extend longevity. Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to senescence-associated diseases and conditions that diminish healthspan, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as many indications that impact quality-of-life that are not life-threatening. The Company’s lead product candidate, HCW9302, was developed using the Company’s legacy TOBI™ (Tissue factOr-Based fusIon) platform. The Company has created another drug discovery technology, the TRBC platform, which is not based on Tissue Factor. The TRBC platform has the capability to construct immunotherapeutics that not only activate and target immune responses but are also equipped with receptors that specifically target cancerous or infected cells. This platform is a versatile scaffold that enables the creation of multiple classes of immunotherapeutic compounds: Class I: Multi-Functional Immune Cell Stimulators; Class II: Second-Generation Immune Checkpoint Inhibitors; Class III: Multi-Specific Targeting Fusions and Enhanced Immune Cell Engagers. These novel immunotherapeutics can be used to treat a wide range of disease indications, including oncology, autoimmune diseases, and improving quality of life conditions. The Company has constructed over 50 molecules using the TRBC platform, including HCW11-002, HCW11-006, HCW11-018 and HCW11-027. Further preclinical evaluation studies are currently being conducted for these three molecules the Company has selected based on promising early data. The Company has two licensing programs in which it has licensed exclusive rights for some of its proprietary molecules. See the Company Pipeline at https://hcwbiologics.com/pipeline/ Company Contact: Rebecca Byam CFO HCW Biologics Inc. rebeccabyam@hcwbiologics.com

Immunotherapy

100 Deals associated with Tobramycin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00063	Tobramycin	S01AA12 J01GB01	DB00684

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Bronchiectasis	China	Joincare Pharmaceutical Group Industry Co., Ltd.	11 Oct 2022
Cystic Fibrosis	Japan	Viatris Healthcare GK	28 Sep 2012
Cystic Fibrosis	Japan	Viatris Pharmaceutical GK	28 Sep 2012
Infectious Lung Disorder	European Union	Viatris Healthcare (Pty) Ltd.	20 Jul 2011
Infectious Lung Disorder	Iceland	Viatris Healthcare (Pty) Ltd.	20 Jul 2011
Infectious Lung Disorder	Liechtenstein	Viatris Healthcare (Pty) Ltd.	20 Jul 2011
Infectious Lung Disorder	Norway	Viatris Healthcare (Pty) Ltd.	20 Jul 2011
Pseudomonas Infections	United States	Viatris Specialty LLC	22 Dec 1997
Pseudomonas Infections	United States	Viatris, Inc.	22 Dec 1997
Acute Bronchitis	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Cystitis	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Hemorrhagic Septicemia	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Peritonitis	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Pneumonia	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Pyelonephritis	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Pyoderma	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Secondary infection	Japan	Towa Pharmaceutical Co., Ltd.	01 Mar 1986
Blepharitis	Japan	Nitto Medic Co., Ltd.	07 Dec 1981
Conjunctivitis	Japan	Nitto Medic Co., Ltd.	07 Dec 1981
Corneal Ulcer	Japan	Nitto Medic Co., Ltd.	07 Dec 1981

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pseudomonas aeruginosa infection	Phase 3	Estonia	Novartis Pharmaceuticals Canada, Inc.	12 Aug 2009
Pseudomonas aeruginosa infection	Phase 3	Russia	Novartis Pharmaceuticals Canada, Inc.	12 Aug 2009
Cataract	Phase 3	United States	Bausch & Lomb, Inc.	01 Feb 2009
Eye Infections	Phase 3	United States	Bausch & Lomb, Inc.	01 Jul 2005
Postoperative Complications	Phase 3	United States	Bausch & Lomb, Inc.	01 Jul 2005
Non-cystic fibrosis bronchiectasis	Phase 2	Belgium	Novartis Pharmaceuticals Corp.	08 Feb 2017
Non-cystic fibrosis bronchiectasis	Phase 2	France	Novartis Pharmaceuticals Corp.	08 Feb 2017
Non-cystic fibrosis bronchiectasis	Phase 2	Germany	Novartis Pharmaceuticals Corp.	08 Feb 2017
Non-cystic fibrosis bronchiectasis	Phase 2	Italy	Novartis Pharmaceuticals Corp.	08 Feb 2017
Non-cystic fibrosis bronchiectasis	Phase 2	Spain	Novartis Pharmaceuticals Corp.	08 Feb 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03705962 (CTgov)	Phase 3	Fractures, Open \| Infectious Diseases	11	Tobramycin (Antibiotic)	lxinafidxj = ftwgqvibnf ylttfkoauq (mcnichhbyz, dhjmldpgiy - bchjfnktom) View more	-	15 Jun 2023
				Placebo: normal saline (Normal Saline)	lxinafidxj = chmkgsqivh ylttfkoauq (mcnichhbyz, ysgtzjkdgz - vwerdlxozb) View more
NCT02478710 (AAINTVAP, CTgov)	Phase 4	Pneumonia, Ventilator-Associated	16	Aerosolized Placebo (Aerosolized Placebo)	wdayblbzww(bxnammzrqn) = pwbfbpxjzp wwfxndwntn (wiaanswuzo, gogbucyavf - undcjyidhr) View more	-	22 May 2023
				Tobramycin+Vancomycin (Aerosolized Tobramycin or Vancomycin)	wdayblbzww(bxnammzrqn) = gqmhkkhjip wwfxndwntn (wiaanswuzo, zfwcpvvesv - chpelsfdwp) View more
NCT02657473 (The BATTLE study, Pubmed \| Respir Res)	Phase 2/3	Non-cystic fibrosis bronchiectasis Maintenance	58	Tobramycin inhalation solution (TIS)	nleoffbgeu(auypgxswka): RR = 0.74 (95% CI, 0.49 - 1.14), P-Value = 0.15	-	03 Dec 2022
				Placebo
NCT02918409 (CTgov)	Phase 4	Cystic Fibrosis	51	Colistin (Standard Colistin Arm)	ayuobjfnco(myibcqrdhf) = swpeskpsza ofvorxmjue (dsjmgnfuja, 9.5) View more	-	06 Oct 2022
				Colistin (Modified Colistin Arm)	ayuobjfnco(myibcqrdhf) = fevnplatjn ofvorxmjue (dsjmgnfuja, 3.0) View more
NCT03673956 (CTgov)	Phase 1/2	Chronic sinusitis	19	Tobramycin (Tobramycin Topical Antibiotic Nasal Saline Rinse)	chovuapkmb = isuhbmjanb ajjvhknbpz (xwcajencvo, tqiqjobozj - yebdhayjwl) View more	-	20 Apr 2022
				levofloxacin (Levofloxacin Topical Antibiotic Nasal Saline Rinse)	chovuapkmb = rljdbhrych ajjvhknbpz (xwcajencvo, owdsvfzpjw - lclsyewwzn) View more
NCT01069705 (CTgov)	Phase 3	Pseudomonas Infections \| Pseudomonas aeruginosa infection \| Cystic Fibrosis ... View more	49	Tobramycin inhalation powder	vankoqsgya = dwikpxrjnm bazolqenql (szlahooqsa, rjnmtulfwq - lgnsmzxdjc) View more	-	02 Jun 2021
MO294 (ERA2021)	Not Applicable	Glomerulosclerosis, Focal Segmental	200	TIP (Cellular variant of primary FSGS)	exbwrtjgqx(uezfzuhuge) = qwhybwimro soldsjdxer (xmnwgpluuj )	Positive	29 May 2021
NCT02712983 (iBEST study, Pubmed \| Eur Respir J)	Phase 2	Non-cystic fibrosis bronchiectasis Pseudomonas aeruginosa	107	Tobramycin inhalation powder (TIP) 84mg once daily	yzsrqzqzax(prvdfpdkgz) = 37.4% ekpgntwnlg (mxhnmhvnax ) View more	-	01 Jan 2021
				Tobramycin inhalation powder (TIP) 140mg once daily
NCT02212587 (CTgov)	Phase 1	Cystic Fibrosis \| Burkholderia Infections	10	TOBI	swqorhfonf(himwxalqhj) = vpfsxmmcvn vzmonakhqb (kdrlowvonl, jphtmwrizv - wszknztnno) View more	-	04 Nov 2020